Q-omics provides the consensus-scored NT5C3AP1 profile across patient tissues and cancer cell-line models. NT5C3AP1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, NT5C3AP1 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, NT5C3AP1 RNA expression shows 13,376 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight THCA, KIRC, and UVM as cancer lineages where NT5C3AP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NT5C3AP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NT5C3AP1 survival associations across molecular data types. NT5C3AP1 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NT5C3AP1 RNA expression–survival associations across cancer types. High NT5C3AP1 expression shows unfavorable associations in LIHC, KICH and LGG, but favorable associations in THCA, LUSC and MESO. The THCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for NT5C3AP1 RNA expression.
This table summarizes NT5C3AP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NT5C3AP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NT5C3AP1 shows higher tumor expression in KIRC, LIHC, CHOL, ESCA, STAD and BRCA. The KIRC box plot shows higher NT5C3AP1 RNA expression in tumor versus normal tissue (log2 FC = +0.269, t-test p < 0.001).
This table shows molecular features associated with NT5C3AP1 in patient tissues and cancer cell lines. In patient samples, NT5C3AP1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
